🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Exenatide in #IIH shows benefit not just for #ICP but also #headaches and #vision. Very important phase 2 trial. academic.oup.com/brain/advance-… @IIHDrBirmingham Dr Susan Mollan University Hospitals Birmingham Uni of Birmingham IIH UK NANOS European Headache Federation Invex Therapeutics @IMSR_UoB

The phase 3 trial IIH Evolve is now recruiting in Australia mivision mivision.com.au/2023/03/patien… #IIH Dr Clare Fraser AnnekeVdWalt Australian and New Zealand Headache Society IH Australia IIH UK Faraidoon Haghdoost (Big Head Pain)

Pressure was lowered at 2.5hr 24hr and 12weeks following drug and visual acuity 👁️ and headache😣improved - a very promising trial for #IIH patients where treatment is currently an unmet need! academic.oup.com/brain/advance-… James L. Mitchell @IIHDrBirmingham Dr Susan Mollan

Hello to Jenna, our new amazing Dietician in our Comprehensive IIH clinic The Alfred! So excited to provide proper care for people with#IIH.

dailymail.co.uk/health/article…

Idiopathic intracranial hypertension #IIH is a disorder featuring raised intracranial pressure and chronic headache. There is no licensed therapy for IIH however a new trial by James L. Mitchell show that diabetes drug Exenatide can reduce pressure in IIH: doi.org/10.1093/brain/…

$IXC was today pleased to announce approval for #IIH EVOLVE clinical trial in Israel today on ASX. Please see invextherapeutics.com/asx-announceme… for details.

Here we go again! $IXC today announced regulatory approval and ethics committee clearance in France to commence recruitment of the #IIH EVOLVE Phase 3 trial 🇫🇷 please see : invextherapeutics.com/asx-announceme…

pubmed.ncbi.nlm.nih.gov/36907221/ The effect of glucagon-like peptide-1 (GLP-1) receptor agonist exenatide on IIH was confirmed by a randomized clinical trial in the UK. At 12 weeks, the intracranial pressure was lowered by 5.6 ± 3.0 cmCSF. #NewKnowledge #nanos #IIH #intracranialpressure

$IXC is pleased to announce the European Medicines Agency (EMA) has granted Exenatide orphan drug designation for Traumatic Brain Injury (TBI). There are no EMA or FDA approved therapies specifically for the treatment of intracranial hypertension in this patient population.

See our announcement on our ASX Release on #ODD designation from the #EMA for #TBI here 👇👇 invextherapeutics.com/asx-announceme…

$IXC today announced a proposed $14.0m capital return to shareholders. To focus on TBI and glaucoma programs. See here 👇for more details : invextherapeutics.com/asx-announceme…

Invex Therapeutics is thrilled to be joining over 20,000 of the worlds leading innovators in Boston this week for the world's largest bio tech conference. #BIO2025 is in full swing and we can't wait! 🧬⚙️🩸🔬⚕️ #BIO2025 #biotech #Invex #IXC $IXC #ausbiotech Biotechnology Innovation Organization

⚕️Invex are proud to be attending the world’s premier biotechnology conference in Boston this week with a packed line up of meetings with investors, partners, & global life sciences leaders underway. 📍Attending #BIO2025? Get in touch, we'd love to connect. #BIO2025 #BIOBoston

Day 1 at #BIO2025 has been non-stop & we wouldn’t have it any other way. From insightful discussions to back-to-back meetings with global leaders in biotech & pharma. Exciting exhibits today from companies like Pfizer Inc. Samsung Bioepis Simcere pharmaceutical Group & more — all focused on

Great to have our Directors, Thomas Duthy and David McAuliffe representing Invex on the ground at #BIO2025 in Boston this week. They’re here meeting with potential partners, investors, and peers — and always open to new conversations around innovation and cutting edge technology.

Day 3 at #BIO2025 has been huge! Biotechnology Innovation Organization #BostonBIO

That’s a wrap on Day 3 of #BIO2025! Another productive day of meetings, insights, and invaluable connections. The global interest in treatments for neurological conditions continues to grow & we’re proud to be part of the conversation. A big thank you to everyone who said hi,

Highlights from Day 3 of #BIO2025 Biotechnology Innovation Organization

This week we released our Quarterly report to the ASX for the June Quarter. Our mission is to unlock our full potential of Exenatide in treating neurological conditions tied to raised intracranial pressure. 📑 Click here to view the full report: tinyurl.com/45bhx4uv #asx